Official US documents have disclosed that a popular anti-stroke medicine may have used fictitious data while concealing research on its fatal effects. In 2009, the acclaimed British medical journal, The Lancet, published a prime story on rivaroxaban, a blood thinner medicine, which showed that the treatment was safe and efficient. But recently, the same journal warned of defaults in the trial data and claimed to initiate an investigation over it.

Lancet opens probe into ‘unreliable’ anti-stroke medicine

royal-society-of-medicine

Royal Society Of Medicine, News on Royal Society Of Medicine, stories on Royal Society Of Medicine, articles on Royal Society Of Medicine, Royal Society Of Medicine stories at Wion, Royal Society Of Medicine news, Royal Society Of Medicine latest news

royal society-of-medicine

Lancet opens probe into ‘unreliable’ anti-stroke medicine